HPLC purity
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
Pepti · Catalog · CagriSema (Cagrilintide + Semaglutide)
GLP-1 / amylin blend · research-use
CagriSema blend OEM supply.
Research-grade cagrilintide + semaglutide co-formulated vials for B2B buyers and private-label brands, shipped with per-component COA.
!
Research use — supplied as research peptides; buyers confirm local compliance
On 2026-04-30 the FDA proposed removing GLP-1 medications from the regulatory bulk-substance framework. Pending finalization, US regulated bulk-substance facilities cannot compound these from bulk substances. Pepti positions GLP-1 compounds for research and private-label brand evaluation worldwide. Read the GLP-1 2026 update →
CagriSemaHPLC ≥ 99%MS confirmed5mg
Vial illustrations reflect supplied lyophilized format. Distribution scope and destination market confirmed before invoicing.
| Compound | CagriSema (Cagrilintide + Semaglutide) |
|---|---|
| Form | Lyophilized powder, glass vial |
| Purity target | ≥ 99% by HPLC |
| Vial formats | 5mg / 20mg |
| Documentation | Batch-linked COA + HPLC chromatogram + MS identity record for every production lot |
| Distribution scope | Research use, worldwide |
| Storage | Lyophilized powder: store at -20°C, protected from light and moisture; typically stable 24+ months. After reconstitution, hold at 2-8°C and use within the validated study window. Ships cold-chain with ice packs. |
MOQ & lead time
| Tier | Quantity | Lead time |
|---|---|---|
| OEM lot | 50 kits (500 vials) | 5–10 days |
| Production lot | 500–2,000 vials | 14–21 days |
| OEM repeat | 2,000+ vials | 21–28 days, scheduled |
Supplied as a research-use peptide. Every quote confirms current-batch COA, purity, destination market and buyer track before invoicing.
Overview
About CagriSema (Cagrilintide + Semaglutide).
CagriSema is a fixed-ratio co-formulation of two distinct peptides: cagrilintide, a long-acting amylin/calcitonin receptor agonist (CAS 1415456-99-3), and semaglutide, a GLP-1 receptor agonist (CAS 910463-68-2). Because the material combines two separate active peptides, the blend carries no single CAS number, molecular formula, or molecular weight; each component is characterized independently by HPLC and mass spectrometry.
Documentation
Batch documentation support for CagriSema (Cagrilintide + Semaglutide) lots.
batch-linked COA, HPLC chromatogram and MS identity record for every production lot. Distribution scope confirmed before invoicing.
MS identity
Mass spectrometry identity confirmation against the CagriSema (Cagrilintide + Semaglutide) reference profile.
Lot traceability
Compound prefix and lot serial printed on the vial label and repeated in the document pack and carton.
FAQ
CagriSema (Cagrilintide + Semaglutide) — frequently asked by B2B buyers.
Is CagriSema supplied as one peptide or a blend?
It ships as a co-formulated blend of two separate peptides, cagrilintide and semaglutide, lyophilized together in a single vial. Because it is a two-API blend, there is no single CAS number or molecular weight; each component is identified and quantified independently on the COA.
What vial sizes, ratios and MOQ are available?
Standard research vials are offered at 5 mg and 20 mg total peptide, with a minimum order of 50 kits (500 vials). The cagrilintide-to-semaglutide ratio can be specified per project; contact us for custom ratios or fill volumes.
What documentation ships with each lot?
Every lot includes a Certificate of Analysis reporting HPLC purity and mass-spectrometry (MS) identity for both components, plus appearance, peptide content, and residual water/solvent data. Independent third-party verification is available on request.
Can Pepti private-label or customize the fill?
Yes. As an OEM and private-label manufacturer we support custom vial labeling, box and blister packaging, blend-ratio adjustments, and bulk API supply. Send your artwork and specifications with the RFQ.
What is the compliance status of this material?
It is supplied strictly as a research-use, laboratory reference material for B2B buyers, not for consumer or veterinary use. The branded finished combination is an investigational drug under regulatory review; buyers are responsible for import, labeling, and end-use compliance in their own jurisdiction.
Related compounds